Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Johnson SM, Khararjian A, Legesse TB, Khani F, Robinson BD, Epstein JI, et al. Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6. Am J Clin Pathol. 2021;155(4):588-596.

Chan A, Carniello JV, Gao Q, Sigler A, Baik J, Roshal M, et al. Role of Flow Cytometric Immunophenotyping for Classic Hodgkin Lymphoma in Small Biopsy and Cytology Specimens. Arch Pathol Lab Med. 2021.

Allen ES, Cohn CS, Bakhtary S, Dunbar NM, Gniadek T, Hopkins CK, et al. Current advances in transfusion medicine 2020: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. Transfusion. 2021;61(9):2756-2767.

Wang TZ, Simon MS, Westblade LF, Saiman L, E Furuya Y, Calfee DP. Quantitative characterization of high-touch surfaces in emergency departments and hemodialysis facilities. Infect Control Hosp Epidemiol. 2021;42(4):474-476.

Huang J, Linares JF, Duran A, Xia W, Saltiel AR, Müller TD, et al. NBR1 is a critical step in the repression of thermogenesis of p62-deficient adipocytes through PPARγ. Nat Commun. 2021;12(1):2876.

Matrai CE, Ohara K, Eng KW, Glynn SM, Chandra P, Chatterjee-Paer S, et al. Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence. Int J Gynecol Pathol. 2021.

Leo P, Chandramouli S, Farré X, Elliott R, Janowczyk A, Bera K, et al. Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2. Eur Urol Focus. 2021;7(4):722-732.

Simonson PD, Wu Y, Wu D, Fromm JR, Lee AY. De Novo Identification and Visualization of Important Cell Populations for Classic Hodgkin Lymphoma Using Flow Cytometry and Machine Learning. Am J Clin Pathol. 2021.

Ma L, Zhao Z, Racine-Brzostek SE, Yang HS. A rare case of persistent pseudohypobicarbonatemia arising from chemistry analyzer-specific interference. Clin Chim Acta. 2021;519:308-310.

Shigeta S, Lui GY, Shaw R, Moser R, Gurley KE, Durenberger G, et al. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Mol Cancer Ther. 2021;20(4):691-703.